| Trial ID: | L5324 |
| Source ID: | NCT05689099
|
| Associated Drug: |
Semaglutide B, 1.34 Mg/Ml
|
| Title: |
A Research Trial Looking at the Comparability of 2 Different Concentrations of Semaglutide for the 0.5 Milligram (mg) Dose
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2|Healthy Participants
|
| Interventions: |
DRUG: Semaglutide B, 1.34 mg/mL|DRUG: Semaglutide B, 0.68 mg/mL
|
| Outcome Measures: |
Primary: AUC0-last,sema 0.5mg: Area under the semaglutide concentration time curve from time 0 until last quantifiable measurement after single dose of subcutaneous semaglutide 0.5 mg, Measured in hours\*nanomoles per liter (h\*nmol/L)., 0-840 hours after a single dose of s.c. semaglutide 0.5 mg|Cmax,sema,0.5mg: maximum observed semaglutide concentration-time after single dose of subcutaneous semaglutide 0.5 mg administration, Measured in nanomoles per liter (nmol/L)., 0-840 hours after a single dose of s.c. semaglutide 0.5 mg |
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
20
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2023-01-17
|
| Completion Date: |
2023-05-30
|
| Results First Posted: |
|
| Last Update Posted: |
2024-10-15
|
| Locations: |
Altasciences Clinical LA, Inc., Cypress, California, 90630, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT05689099
|
